Literature DB >> 25467940

BRAF inhibitors: experience in thyroid cancer and general review of toxicity.

M E Cabanillas1, A Patel, B P Danysh, R Dadu, S Kopetz, G Falchook.   

Abstract

The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas but have limited efficacy in BRAF-mutant colorectal cancer. Little is known at this time regarding BRAF inhibitors in thyroid cancer. Initial reports in patients with progressive, radioactive iodine-refractory BRAF-mutant papillary thyroid cancer suggest response rates of approximately 30-40%. In this review, we discuss BRAF inhibitors in the context of thyroid cancer, the toxicities associated with BRAF inhibitors, and the suggested management of those toxicities. The management of vemurafenib and dabrafenib toxicities is applicable across all tumor types and may serve as a practical guide to their use.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25467940      PMCID： PMC4312215          DOI： 10.1007/s12672-014-0207-9

Source DB:  PubMed          Journal:  Horm Cancer        ISSN： 1868-8497            Impact factor:   3.869


  115 in total

1.  Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.

Authors:  David S Hong; Maria E Cabanillas; Jennifer Wheler; Aung Naing; Apostolia M Tsimberidou; Lei Ye; Naifa L Busaidy; Steven G Waguespack; Mike Hernandez; Adel K El Naggar; Alder K El Naggar; Savita Bidyasar; John Wright; Steven I Sherman; Razelle Kurzrock
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

2.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

3.  [Vemurafenib-induced toxic epidermal necrolysis].

Authors:  M Wantz; I Spanoudi-Kitrimi; A Lasek; D Lebas; J-F Quinchon; P Modiano
Journal:  Ann Dermatol Venereol       Date:  2013-12-14       Impact factor: 0.777

4.  Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension.

Authors:  Julio Ricarte-Filho; Ian Ganly; Michael Rivera; Nora Katabi; Weimin Fu; Ashok Shaha; R Michael Tuttle; James A Fagin; Ronald Ghossein
Journal:  Thyroid       Date:  2012-04-03       Impact factor: 6.568

5.  Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.

Authors:  Emily Y Chu; Karolyn A Wanat; Christopher J Miller; Ravi K Amaravadi; Leslie A Fecher; Marcia S Brose; Suzanne McGettigan; Lydia R Giles; Lynn M Schuchter; John T Seykora; Misha Rosenbach
Journal:  J Am Acad Dermatol       Date:  2012-05-18       Impact factor: 11.527

6.  Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.

Authors:  Peng Hou; Dingxie Liu; Yuan Shan; Shuiying Hu; Kimberley Studeman; Stephen Condouris; Yangang Wang; Ariel Trink; Adel K El-Naggar; Giovanni Tallini; Vasily Vasko; Mingzhao Xing
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

7.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

8.  Progression of RAS-mutant leukemia during RAF inhibitor treatment.

Authors:  Margaret K Callahan; Raajit Rampal; James J Harding; Virginia M Klimek; Young Rock Chung; Taha Merghoub; Jedd D Wolchok; David B Solit; Neal Rosen; Omar Abdel-Wahab; Ross L Levine; Paul B Chapman
Journal:  N Engl J Med       Date:  2012-11-07       Impact factor: 91.245

9.  COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Authors:  Cory M Johannessen; Jesse S Boehm; So Young Kim; Sapana R Thomas; Leslie Wardwell; Laura A Johnson; Caroline M Emery; Nicolas Stransky; Alexandria P Cogdill; Jordi Barretina; Giordano Caponigro; Haley Hieronymus; Ryan R Murray; Kourosh Salehi-Ashtiani; David E Hill; Marc Vidal; Jean J Zhao; Xiaoping Yang; Ozan Alkan; Sungjoon Kim; Jennifer L Harris; Christopher J Wilson; Vic E Myer; Peter M Finan; David E Root; Thomas M Roberts; Todd Golub; Keith T Flaherty; Reinhard Dummer; Barbara L Weber; William R Sellers; Robert Schlegel; Jennifer A Wargo; William C Hahn; Levi A Garraway
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962

10.  Uveitis as a Result of MAP Kinase Pathway Inhibition.

Authors:  Lavnish Joshi; Andreas Karydis; Maria Gemenetzi; Emily H Shao; Simon R J Taylor
Journal:  Case Rep Ophthalmol       Date:  2013-11-30
View more
  23 in total

Review 1.  Update on the systemic management of radioactive iodine refractory differentiated thyroid cancer (Review).

Authors:  Geethu Babu; Cessal Thommachan Kainickal
Journal:  Mol Clin Oncol       Date:  2020-12-24

2.  Novel three-dimensional cultures provide insights into thyroid cancer behavior.

Authors:  Mason A Lee; Kensey N Bergdorf; Courtney J Phifer; Caroline Y Jones; Sonia Y Byon; Leah M Sawyer; Joshua A Bauer; Vivian L Weiss
Journal:  Endocr Relat Cancer       Date:  2020-02       Impact factor: 5.678

3.  Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair.

Authors:  Ryan Robb; Linlin Yang; Changxian Shen; Adam R Wolfe; Amy Webb; Xiaoli Zhang; Marall Vedaie; Motoyasu Saji; Sissy Jhiang; Matthew D Ringel; Terence M Williams
Journal:  Clin Cancer Res       Date:  2019-05-16       Impact factor: 12.531

Review 4.  Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.

Authors:  Elham Patrad; Solmaz Khalighfard; Taghi Amiriani; Vahid Khori; Ali Mohammad Alizadeh
Journal:  Cell Oncol (Dordr)       Date:  2022-09-23       Impact factor: 7.051

5.  Construction of a Tumor Immune Microenvironment-Related Prognostic Model in BRAF-Mutated Papillary Thyroid Cancer.

Authors:  Yuxiao Xia; Xue Jiang; Yuan Huang; Qian Liu; Yin Huang; Bo Zhang; Zhanjun Mei; Dongkun Xu; Yuhong Shi; Wenling Tu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-08       Impact factor: 6.055

6.  Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy.

Authors:  Mona M Sabra; Eric Sherman; Robert Michael Tuttle
Journal:  Clin Endocrinol (Oxf)       Date:  2019-02-21       Impact factor: 3.478

7.  Evaluating the effectiveness of targeted therapies for thyroid carcinoma: an updated meta-analysis.

Authors:  Shuai Lin; Jun Shen; Wanjun Zhao; Xiaofei Wang; Xiaoqing Wang; Jingqiang Zhu
Journal:  Ann Transl Med       Date:  2019-12

Review 8.  Recent advances in managing differentiated thyroid cancer.

Authors:  Livia Lamartina; Giorgio Grani; Cosimo Durante; Sebastiano Filetti
Journal:  F1000Res       Date:  2018-01-18

9.  High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor.

Authors:  Le Zhang; Zhaoying Yang; Letizia Granieri; Adrian Pasculescu; Alessandro Datti; Sylvia L Asa; Zheli Xu; Shereen Ezzat
Journal:  Oncotarget       Date:  2016-04-12

10.  Galectin-1 is a diagnostic marker involved in thyroid cancer progression.

Authors:  Vanessa Arcolia; Fabrice Journe; Aurore Wattier; Emmanuelle Leteurtre; Florence Renaud; Hans-Joachim Gabius; Myriam Remmelink; Christine Decaestecker; Alexandra Rodriguez; Sébastien Boutry; Sophie Laurent; Sven Saussez
Journal:  Int J Oncol       Date:  2017-07-04       Impact factor: 5.650
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.